Regarding its role in multiple myeloma, one case-control study showed that serum resistin was lower in MM patients (n = 73, 9.4 ± 5.0 ng/mL) compared to gender and age-matched healthy controls (n = 73, 15.9 ± 6.8 ng/mL, p < 0.001) [87]. Here, RETN is linked to plasma cell myeloma.